AbbVie Inc (ABBV)vsCaribou Biosciences Inc (CRBU)
ABBV
AbbVie Inc
$288.85
-2.05%
HEALTHCARE · Cap: $521.11B
CRBU
Caribou Biosciences Inc
$0.42
-4.90%
HEALTHCARE · Cap: $55.64M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 657738% more annual revenue ($66.01B vs $10.04M). ABBV leads profitability with a 15.7% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
CRBU
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.85
$132.01 premium
Margin of Safety
+30.0%
Fair Value
$2.27
Current Price
$0.42
$1.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : CRBU
The primary concerns for CRBU are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while CRBU is a value play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.31 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 26/100), backed by strong 15.7% margins and 10.3% revenue growth. CRBU offers better value entry with a 30.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?